ILiAD Biotechnologies

ILiAD Biotechnologies, LLC (ILiAD) is a clinical-stage biotechnology company dedicated to the prevention and treatment of diseases caused by Bordetella pertussis. ILiAD's lead candidate is BPZE1, a live attenuated pertussis vaccine, which has successfully completed a Phase 1 human clinical trial.